Amphix Bio
Phase 1Amphix Bio is a preclinical stage company developing a new platform technology, Supramolecular Therapeutic Peptides (STPs), that modifies immunological response and initiates regenerative processes to restore function lost from injury, disease, or aging. These therapies trigger targeted signaling pathways while forming scaffolds to support biological repair. Amphix Bio's goal is to increase human healthspan — the length of time that people can live productive, fulfilling lives.
About
Amphix Bio is a preclinical stage company developing a new platform technology, Supramolecular Therapeutic Peptides (STPs), that modifies immunological response and initiates regenerative processes to restore function lost from injury, disease, or aging. These therapies trigger targeted signaling pathways while forming scaffolds to support biological repair. Amphix Bio's goal is to increase human healthspan — the length of time that people can live productive, fulfilling lives.
Funding History
1Total raised: $4M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile